|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 322.90 USD | -2.56% |
|
-5.20% | +74.81% |
| 11-26 | Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Ahead of Key Economic Data Deluge | MT |
| 11-26 | BeOne Medicine Wins FDA Priority Review for Mantle Cell Lymphoma Drug | MT |
| Capitalization | 35.73B 30.71B 28.77B 26.82B 49.53B 3,216B 53.88B 337B 130B 1,519B 134B 131B 5,553B | P/E ratio 2025 * |
104x | P/E ratio 2026 * | 48.1x |
|---|---|---|---|---|---|
| Enterprise value | 33.39B 28.7B 26.89B 25.06B 46.29B 3,005B 50.35B 315B 121B 1,419B 125B 123B 5,190B | EV / Sales 2025 * |
6.32x | EV / Sales 2026 * | 5.11x |
| Free-Float |
96.17% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: BeOne Medicines AG
| 1 day | -2.56% | ||
| 1 week | -5.20% | ||
| Current month | -5.20% | ||
| 1 month | -2.85% | ||
| 3 months | -5.53% | ||
| 6 months | +26.20% | ||
| Current year | +74.81% |
| 1 week | 310.11 |  | 340.98 |
| 1 month | 310.11 | | 385.22 |
| Current year | 172.67 | | 385.22 |
| 1 year | 170.99 | | 385.22 |
| 3 years | 126.97 | | 385.22 |
| 5 years | 118.18 | | 426.56 |
| 10 years | 22.51 | | 426.56 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Oyler
CEO | Chief Executive Officer | 56 | 27/10/2010 |
Xiao Bin Wu
PSD | President | 63 | 31/03/2018 |
Aaron Rosenberg
DFI | Director of Finance/CFO | 49 | 21/07/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
John Oyler
CHM | Chairman | 56 | 26/01/2016 |
Michael Goller
BRD | Director/Board Member | 50 | 31/03/2015 |
Ranjeev Krishana
BRD | Director/Board Member | 51 | 30/09/2014 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.56% | -5.20% | +57.04% | +72.14% | 35.73B | |
| -0.95% | -1.24% | +4.02% | +12.98% | 47.37B | |
| +0.41% | -1.81% | +11.46% | +7.61% | 38.46B | |
| +0.38% | -1.24% | +11.14% | +21.03% | 27.23B | |
| +0.61% | -7.48% | +56.37% | +169.06% | 15.44B | |
| +1.48% | +2.42% | +65.68% | +225.06% | 15.4B | |
| +0.05% | +0.47% | -14.53% | -7.21% | 14.19B | |
| +0.43% | -1.63% | +51.98% | - | 13.64B | |
| -0.16% | -1.27% | +114.33% | +114.78% | 13.23B | |
| -1.51% | -3.24% | +54.47% | +70.26% | 12.55B | |
| Average | -0.18% | -2.03% | +41.19% | +76.19% | 23.32B | |
| Weighted average by Cap. | -0.40% | -2.15% | +32.38% | +56.61% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 5.29B 4.54B 4.26B 3.97B 7.33B 476B 7.97B 49.79B 19.23B 225B 19.84B 19.42B 822B | 6.41B 5.51B 5.16B 4.81B 8.88B 577B 9.66B 60.34B 23.3B 272B 24.04B 23.53B 996B |
| Net income | 319M 274M 257M 240M 443M 28.74B 481M 3.01B 1.16B 13.57B 1.2B 1.17B 49.62B | 700M 601M 563M 525M 970M 62.97B 1.06B 6.59B 2.54B 29.74B 2.63B 2.57B 109B |
| Net Debt | -2.34B -2.01B -1.88B -1.76B -3.24B -210B -3.53B -22.03B -8.5B -99.4B -8.78B -8.59B -363B | -2.99B -2.57B -2.4B -2.24B -4.14B -269B -4.5B -28.13B -10.86B -127B -11.21B -10.97B -464B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/12/25 | 322.90 $ | -2.56% | 603,844 |
| 04/12/25 | 331.40 $ | -1.91% | 239,751 |
| 03/12/25 | 337.86 $ | +2.32% | 170,607 |
| 02/12/25 | 330.18 $ | -1.61% | 181,578 |
| 01/12/25 | 335.60 $ | -1.47% | 198,657 |
Delayed Quote Nasdaq, December 05, 2025 at 09:00 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ONC Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition